Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells

Thomas McFate, Ahmed Mohyeldin, Huasheng Lu, Jay Thakar, Jeremy Henriques, Nader D. Halim, Hong Wu, Michael J. Schell, Mon Tsang Tsz, Orla Teahan, Shaoyu Zhou, Joseph A. Califano, Ho Jeoung Nam, Robert Harris, Ajay Verma

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

High lactate generation and low glucose oxidation, despite normal oxygen conditions, are commonly seen in cancer cells and tumors. Historically known as the Warburg effect, this altered metabolic phenotype has long been correlated with malignant progression and poor clinical outcome. However, the mechanistic relationship between altered glucose metabolism and malignancy remains poorly understood. Here we show that inhibition of pyruvate dehydrogenase complex (PDC) activity contributes to the Warburg metabolic and malignant phenotype in human head and neck squamous cell carcinoma. PDC inhibition occurs via enhanced expression of pyruvate dehydrogenase kinase-1 (PDK-1), which results in inhibitory phosphorylation of the pyruvate dehydrogenase α (PDHα) subunit. We also demonstrate that PDC inhibition in cancer cells is associated with normoxic stabilization of the malignancy-promoting transcription factor hypoxia-inducible factor-1α (HIF-1α) by glycolytic metabolites. Knockdown of PDK-1 via short hairpin RNA lowers PDHα phosphorylation, restores PDC activity, reverts the Warburg metabolic phenotype, decreases normoxic HIF-1α expression, lowers hypoxic cell survival, decreases invasiveness, and inhibits tumor growth. PDK-1 is an HIF-1-regulated gene, and these data suggest that the buildup of glycolytic metabolites, resulting from high PDK-1 expression, may in turn promote HIF-1 activation, thus sustaining a feed-forward loop for malignant progression. In addition to providing anabolic support for cancer cells, altered fuel metabolism thus supports a malignant phenotype. Correction of metabolic abnormalities offers unique opportunities for cancer treatment and may potentially synergize with other cancer therapies.

Original languageEnglish
Pages (from-to)22700-22708
Number of pages9
JournalJournal of Biological Chemistry
Volume283
Issue number33
DOIs
StatePublished - Aug 15 2008

Fingerprint

Pyruvate Dehydrogenase Complex
Hypoxia-Inducible Factor 1
Cells
Phenotype
Phosphorylation
Metabolites
Pyruvic Acid
Metabolism
Tumors
Neoplasms
Oxidoreductases
Glucose
Oncology
Small Interfering RNA
Fuel cells
Lactic Acid
Transcription Factors
Stabilization
Genes
Chemical activation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

McFate, T., Mohyeldin, A., Lu, H., Thakar, J., Henriques, J., Halim, N. D., ... Verma, A. (2008). Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. Journal of Biological Chemistry, 283(33), 22700-22708. https://doi.org/10.1074/jbc.M801765200

Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. / McFate, Thomas; Mohyeldin, Ahmed; Lu, Huasheng; Thakar, Jay; Henriques, Jeremy; Halim, Nader D.; Wu, Hong; Schell, Michael J.; Tsz, Mon Tsang; Teahan, Orla; Zhou, Shaoyu; Califano, Joseph A.; Nam, Ho Jeoung; Harris, Robert; Verma, Ajay.

In: Journal of Biological Chemistry, Vol. 283, No. 33, 15.08.2008, p. 22700-22708.

Research output: Contribution to journalArticle

McFate, T, Mohyeldin, A, Lu, H, Thakar, J, Henriques, J, Halim, ND, Wu, H, Schell, MJ, Tsz, MT, Teahan, O, Zhou, S, Califano, JA, Nam, HJ, Harris, R & Verma, A 2008, 'Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells', Journal of Biological Chemistry, vol. 283, no. 33, pp. 22700-22708. https://doi.org/10.1074/jbc.M801765200
McFate, Thomas ; Mohyeldin, Ahmed ; Lu, Huasheng ; Thakar, Jay ; Henriques, Jeremy ; Halim, Nader D. ; Wu, Hong ; Schell, Michael J. ; Tsz, Mon Tsang ; Teahan, Orla ; Zhou, Shaoyu ; Califano, Joseph A. ; Nam, Ho Jeoung ; Harris, Robert ; Verma, Ajay. / Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 33. pp. 22700-22708.
@article{e871b69c585d43d7be2f22ce6c4b6512,
title = "Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells",
abstract = "High lactate generation and low glucose oxidation, despite normal oxygen conditions, are commonly seen in cancer cells and tumors. Historically known as the Warburg effect, this altered metabolic phenotype has long been correlated with malignant progression and poor clinical outcome. However, the mechanistic relationship between altered glucose metabolism and malignancy remains poorly understood. Here we show that inhibition of pyruvate dehydrogenase complex (PDC) activity contributes to the Warburg metabolic and malignant phenotype in human head and neck squamous cell carcinoma. PDC inhibition occurs via enhanced expression of pyruvate dehydrogenase kinase-1 (PDK-1), which results in inhibitory phosphorylation of the pyruvate dehydrogenase α (PDHα) subunit. We also demonstrate that PDC inhibition in cancer cells is associated with normoxic stabilization of the malignancy-promoting transcription factor hypoxia-inducible factor-1α (HIF-1α) by glycolytic metabolites. Knockdown of PDK-1 via short hairpin RNA lowers PDHα phosphorylation, restores PDC activity, reverts the Warburg metabolic phenotype, decreases normoxic HIF-1α expression, lowers hypoxic cell survival, decreases invasiveness, and inhibits tumor growth. PDK-1 is an HIF-1-regulated gene, and these data suggest that the buildup of glycolytic metabolites, resulting from high PDK-1 expression, may in turn promote HIF-1 activation, thus sustaining a feed-forward loop for malignant progression. In addition to providing anabolic support for cancer cells, altered fuel metabolism thus supports a malignant phenotype. Correction of metabolic abnormalities offers unique opportunities for cancer treatment and may potentially synergize with other cancer therapies.",
author = "Thomas McFate and Ahmed Mohyeldin and Huasheng Lu and Jay Thakar and Jeremy Henriques and Halim, {Nader D.} and Hong Wu and Schell, {Michael J.} and Tsz, {Mon Tsang} and Orla Teahan and Shaoyu Zhou and Califano, {Joseph A.} and Nam, {Ho Jeoung} and Robert Harris and Ajay Verma",
year = "2008",
month = "8",
day = "15",
doi = "10.1074/jbc.M801765200",
language = "English",
volume = "283",
pages = "22700--22708",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "33",

}

TY - JOUR

T1 - Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells

AU - McFate, Thomas

AU - Mohyeldin, Ahmed

AU - Lu, Huasheng

AU - Thakar, Jay

AU - Henriques, Jeremy

AU - Halim, Nader D.

AU - Wu, Hong

AU - Schell, Michael J.

AU - Tsz, Mon Tsang

AU - Teahan, Orla

AU - Zhou, Shaoyu

AU - Califano, Joseph A.

AU - Nam, Ho Jeoung

AU - Harris, Robert

AU - Verma, Ajay

PY - 2008/8/15

Y1 - 2008/8/15

N2 - High lactate generation and low glucose oxidation, despite normal oxygen conditions, are commonly seen in cancer cells and tumors. Historically known as the Warburg effect, this altered metabolic phenotype has long been correlated with malignant progression and poor clinical outcome. However, the mechanistic relationship between altered glucose metabolism and malignancy remains poorly understood. Here we show that inhibition of pyruvate dehydrogenase complex (PDC) activity contributes to the Warburg metabolic and malignant phenotype in human head and neck squamous cell carcinoma. PDC inhibition occurs via enhanced expression of pyruvate dehydrogenase kinase-1 (PDK-1), which results in inhibitory phosphorylation of the pyruvate dehydrogenase α (PDHα) subunit. We also demonstrate that PDC inhibition in cancer cells is associated with normoxic stabilization of the malignancy-promoting transcription factor hypoxia-inducible factor-1α (HIF-1α) by glycolytic metabolites. Knockdown of PDK-1 via short hairpin RNA lowers PDHα phosphorylation, restores PDC activity, reverts the Warburg metabolic phenotype, decreases normoxic HIF-1α expression, lowers hypoxic cell survival, decreases invasiveness, and inhibits tumor growth. PDK-1 is an HIF-1-regulated gene, and these data suggest that the buildup of glycolytic metabolites, resulting from high PDK-1 expression, may in turn promote HIF-1 activation, thus sustaining a feed-forward loop for malignant progression. In addition to providing anabolic support for cancer cells, altered fuel metabolism thus supports a malignant phenotype. Correction of metabolic abnormalities offers unique opportunities for cancer treatment and may potentially synergize with other cancer therapies.

AB - High lactate generation and low glucose oxidation, despite normal oxygen conditions, are commonly seen in cancer cells and tumors. Historically known as the Warburg effect, this altered metabolic phenotype has long been correlated with malignant progression and poor clinical outcome. However, the mechanistic relationship between altered glucose metabolism and malignancy remains poorly understood. Here we show that inhibition of pyruvate dehydrogenase complex (PDC) activity contributes to the Warburg metabolic and malignant phenotype in human head and neck squamous cell carcinoma. PDC inhibition occurs via enhanced expression of pyruvate dehydrogenase kinase-1 (PDK-1), which results in inhibitory phosphorylation of the pyruvate dehydrogenase α (PDHα) subunit. We also demonstrate that PDC inhibition in cancer cells is associated with normoxic stabilization of the malignancy-promoting transcription factor hypoxia-inducible factor-1α (HIF-1α) by glycolytic metabolites. Knockdown of PDK-1 via short hairpin RNA lowers PDHα phosphorylation, restores PDC activity, reverts the Warburg metabolic phenotype, decreases normoxic HIF-1α expression, lowers hypoxic cell survival, decreases invasiveness, and inhibits tumor growth. PDK-1 is an HIF-1-regulated gene, and these data suggest that the buildup of glycolytic metabolites, resulting from high PDK-1 expression, may in turn promote HIF-1 activation, thus sustaining a feed-forward loop for malignant progression. In addition to providing anabolic support for cancer cells, altered fuel metabolism thus supports a malignant phenotype. Correction of metabolic abnormalities offers unique opportunities for cancer treatment and may potentially synergize with other cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=53049087909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049087909&partnerID=8YFLogxK

U2 - 10.1074/jbc.M801765200

DO - 10.1074/jbc.M801765200

M3 - Article

VL - 283

SP - 22700

EP - 22708

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 33

ER -